Clinical Evidence for the Quadra Allure MP™ CRT-P Pacemaker | Abbott
CARDIOVASCULAR
hamburger
BACK
Quadra Assura MP™ CRT-D
Clinical Evidence

A Growing Body of Evidence for Multipoint™ Pacing

The U.S. IDE Study

Meeting Safety and Efficacy Endpoints1

The recent MultiPoint™ Pacing U.S. IDE study from Tomassoni et al. showed:

  • Safety: 93.2% freedom from system-related complications1
  • Efficacy: MultiPoint™ Pacing technology demonstrated to be noninferior to BiV with respect to non-responder rate1

Converting Non-Responders to Responders1

The sub-analysis study demonstrated that wider cathode spacing and near-simultaneous intraventricular timing delays are best. When MultiPoint™ Pacing technology was programmed with cathode spacing ≥ 30 mm and 5 ms LV delay:

  • CRT response rate was greatest at 87% and the super-responder rate was greatest at 54% (n = 52)1
  • Non-responders were converted to responders (8 of 8 patients)1

Conclusions from the U.S. IDE study include:

  • MultiPoint™ Pacing technology is safe and effective1
  • The enrolled patient population had a high response rate to quadripolar BiV pacing1
  • MultiPoint™ Pacing technology response rates for this patient population are greatest when devices are programmed with wide LV electrode spacing and short intraventricular delay1
  • There is a growing body of evidence that MultiPoint™ Pacing is a feature that physicians can use to potentially improve responder rates1
Graph showing non-responder is greater than responder
Manuscript in JACC: Clinical Electrophysiology

Multipoint Pacing Data from International Studies

Several international studies report results related to improved patient response to CRT with MultiPoint Pacing as compared to single-site pacing.
 

Reported Improvements of CRT Response Rate At 12 Months2

Zanon et al. compared 20 patients optimized with MultiPoint Pacing to 36 patients optimized with traditional BiV pacing and 54 nonoptimized BiV patients.2 The results indicate a progression in response from nonoptimized BiV to optimized BiV to optimized with MultiPoint Pacing at 12 months consistently measured over three definitions of response:

  • 90% response rate with MultiPoint Pacing measured by ESV decrease > 15%2
  • 95% response rate with MultiPoint Pacing measured by ≥ 1 decrease in NYHA class2
  • 90% response rate with MultiPoint Pacing measured by Packer’s score2
Graph showing optimized response proportions
ΔESVi, ΔNYHA, and PACKER’S response rates. Response indicates ΔESVi ≥ 15%, ΔNYHA Class > 0, or PACKER’S score = 0 at follow-up relative to baseline. The vertical segments represent the 95 percent CI of the estimated proportions.


Reported Improvements in Ejection Fraction at 6 Months3

Forleo et al. compared the changes in ejection fraction (EF) in 232 patients with a 6-month follow-up.3 During implant, capture thresholds were measured as well as the presence of PNS. The results show:

  • MPP technology was programmable in 97% of patients3
  • 56% clinical composite score for patients with MPP technology turned on versus 38% in control group3
  • 39% ± 9.6% increase from 28.2% ± 509 in left ventricular EF for patients with MPP technology turned on3
  • 34.6% ± 7.6% increase from 28.1% ± 6.0 in patients with MPP technology turned off3
Graph showing changes in mean left ventricular ejection fraction
In summary, the Italian MPP technology registry (IRON-MPP) study showed QRS was reduced and both EF and clinical composite score improved with MPP technology relative to conventional BiV.³


Building Comprehensive Heart Failure Management

The Quadra Allure MP™ CRT-P Is one of our heart failure management therapies. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about our approach to heart failure management.


Resources and Documentation

Product Manuals (Instructions for Use)

Reimbursement Information

References

  1. Niazi, I., Baker, J., Corbisiero, R., Love, C., Martin, D., Sheppard, R., ... Tomassoni, G., & MPP Investigators. (2017). Safety and efficacy of Multipoint Pacing in cardiac resynchronization therapy: The MultiPoint pacing trial. JACC: Clinical Electrophysiology, 3 (13), 1510-1518. https://www.sciencedirect.com/science/article/pii/S2405500X17306084
  2. Zanon, F., Marcantoni, L., Baracca, E., Pastore, G., Lanza, D., Aggio, A., … Prinzen, F. (2016). Optimization of left ventricular pacing site plus multipoint pacing improves remodeling and clinical response of cardiac resynchronization therapy at 1 year. Heart Rhythm, 13(8),1644-1651. https://www.heartrhythmjournal.com/article/S1547-5271(16)30316-2/fulltext
  3. Forleo, G. B., Santini, L., Giammaria, M., Potenza, D., Curnis, A., Calabrese, V., … Zanon, F. (2016). Multipoint Pacing via a quadripolar left-ventricular lead: Preliminary results from the Italian registry on multipoint left-ventricular pacing in cardiac resynchronization therapy (IRON-MPP). Europace, (17 May 2016), 1-8. https://academic.oup.com/europace/article/19/7/1170/2952316
Important Safety Information
Sign Up for Updates

MAT-2117371 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

Precautions


Please be sure to read it.

The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.

The information provided here is not intended to provide information to patients and the general public.



Are you a healthcare professional?

 

Test

yesno